Anavex Life Sciences Corp (AVXL)

[Lima4918]

Nidan and Investor,

This extract from the patent answers the question of who this "on and off again" Anavex treatment method was performed on. It was performed on 12 of the remaining Alz patients from the original Aussie trial. Small group but this answers the question as to the company's tinkering with the protocol. I mean, it never was a slam dunk as to what dosage amount was optimal, how often, etc. This patent may provide some insight on how Anavex may want to treat the patients in the trials?


Could this be a reason for the holdup of registration?


Company stated it was dosing as "planned" and I believe them, but their probably dosing in this "on and off" fashion?